Contineum Therapeutics (CTNM) Equity Ratio (2023 - 2025)
Contineum Therapeutics (CTNM) has 3 years of Equity Ratio data on record, last reported at 0.95 in Q3 2025.
- For Q3 2025, Equity Ratio fell 2.83% year-over-year to 0.95; the TTM value through Sep 2025 reached 0.95, down 2.83%, while the annual FY2024 figure was 0.93, 278.6% up from the prior year.
- Equity Ratio reached 0.95 in Q3 2025 per CTNM's latest filing, up from 0.94 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.98 in Q2 2024 and bottomed at 0.61 in Q1 2024.
- Average Equity Ratio over 3 years is 0.57, with a median of 0.93 recorded in 2025.
- Peak YoY movement for Equity Ratio: surged 278.6% in 2024, then dropped 4.63% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.52 in 2023, then soared by 278.6% to 0.93 in 2024, then grew by 1.62% to 0.95 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.95 in Q3 2025, 0.94 in Q2 2025, and 0.93 in Q1 2025.